Paper25965342
A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN and 7 others. PLoS One, 2015. Cited by 89 papers, by iCite.
Cite this record
ConductScience Library. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Papers, record 25965342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25965342
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Cisplatin | Major topic |
| DNA Repair | Major topic |
| Pyrazines | Major topic |
| Sulfones | Major topic |
| Ataxia Telangiectasia Mutated Proteins | |
| Cell Line, Tumor | |
| Cell Survival | |
| DNA-Directed DNA Polymerase | |
| Drug Resistance, Neoplasm | |
| Drug Synergism | |
| Gene Library | |
| HCT116 Cells | |
| Humans | |
| Intracellular Signaling Peptides and Proteins | |
| RNA, Small Interfering | |
| Tumor Suppressor p53-Binding Protein 1 |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| T32 CA009582 | NCI NIH HHS | United States | T32CA009582 | PubMed and NIH | NIH RePORTER |
| CA95131 | NCI NIH HHS | United States | PubMed | PubMed | |
| R01 CA102792 | NCI NIH HHS | United States | R01CA102792 | PubMed and NIH | NIH RePORTER |
| R01 CA102729 | NCI NIH HHS | United States | R01CA102729 | PubMed and NIH | NIH RePORTER |
| T32CA093240 | NCI NIH HHS | United States | T32CA093240 | PubMed and NIH | NIH RePORTER |
| T32 GM007347 | NIGMS NIH HHS | United States | T32GM007347 | PubMed | NIH RePORTER |
| T32 CA093240 | NCI NIH HHS | United States | T32CA093240 | PubMed and NIH | NIH RePORTER |
| CA102792 | NCI NIH HHS | United States | R01CA102792 | PubMed and NIH | NIH RePORTER |
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20125090 | Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. | Nat Rev Clin Oncol | 2010 | https://conductscience.org/library/papers/20125090 | PubMed |
| 2 | 23548269 | ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. | Cancer Res | 2013 | https://conductscience.org/library/papers/23548269 | PubMed |
| 3 | 15829956 | DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. | Nature | 2005 | https://conductscience.org/library/papers/15829956 | PubMed |
| 4 | 20453858 | 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. | Nat Struct Mol Biol | 2010 | https://conductscience.org/library/papers/20453858 | PubMed |
| 5 | 23118055 | Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. | Cancer Res | 2012 | https://conductscience.org/library/papers/23118055 | PubMed |
| 6 | 12370818 | Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. | Oncogene | 2002 | https://conductscience.org/library/papers/12370818 | PubMed |
| 7 | 9307278 | Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. | Cancer Res | 1997 | https://conductscience.org/library/papers/9307278 | PubMed |
| 8 | 21069451 | Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. | Breast Cancer Res Treat | 2011 | https://conductscience.org/library/papers/21069451 | PubMed |
| 9 | 21565612 | Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. | Cell | 2011 | https://conductscience.org/library/papers/21565612 | PubMed |
| 10 | 20362325 | 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. | Cell | 2010 | https://conductscience.org/library/papers/20362325 | PubMed |
| 11 | 15829965 | Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. | Nature | 2005 | https://conductscience.org/library/papers/15829965 | PubMed |
| 12 | 2088205 | A three-dimensional model to analyze drug-drug interactions. | Antiviral Res | 1990 | https://conductscience.org/library/papers/2088205 | PubMed |
| 13 | 15701627 | Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15701627 | PubMed |
| 14 | 23394205 | Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. | J Med Chem | 2013 | https://conductscience.org/library/papers/23394205 | PubMed |
| 15 | 22047021 | Translesion DNA synthesis in the context of cancer research. | Cancer Cell Int | 2011 | https://conductscience.org/library/papers/22047021 | PubMed |
| 16 | 20573551 | Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. | DNA Repair (Amst) | 2010 | https://conductscience.org/library/papers/20573551 | PubMed |
| 17 | 15829966 | Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. | Nature | 2005 | https://conductscience.org/library/papers/15829966 | PubMed |
| 18 | 24662920 | ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. | Cancer Res | 2014 | https://conductscience.org/library/papers/24662920 | PubMed |
| 19 | 22246237 | Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. | Mol Cancer Res | 2012 | https://conductscience.org/library/papers/22246237 | PubMed |
| 20 | 18594563 | ATR: an essential regulator of genome integrity. | Nat Rev Mol Cell Biol | 2008 | https://conductscience.org/library/papers/18594563 | PubMed |
Cited by60
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882893 | Chk1/2 Inhibition by AZD7762 Enhances Andrographolide-Induced DNA Damage, Impairs DNA Repair, and Promotes Apoptosis in Head and Neck Squamous Cell Carcinoma CAL-33 Cells. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882893 | PubMed |
| 40067909 | NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage. | Sci Signal | 2025 | https://conductscience.org/library/papers/40067909 | PubMed |
| 39841295 | Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). | Cancer Chemother Pharmacol | 2025 | https://conductscience.org/library/papers/39841295 | PubMed |
| 39707666 | Synergistic Potential of Argentatins A and B to Improve 5-Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. | J Cell Mol Med | 2024 | https://conductscience.org/library/papers/39707666 | PubMed |
| 39156700 | Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer. | Front Oncol | 2024 | https://conductscience.org/library/papers/39156700 | PubMed |
| 39135999 | Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer. | Front Oncol | 2024 | https://conductscience.org/library/papers/39135999 | PubMed |
| 38201511 | Exploiting the DNA Damage Response for Prostate Cancer Therapy. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38201511 | PubMed |
| 38041093 | The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis. | J Transl Med | 2023 | https://conductscience.org/library/papers/38041093 | PubMed |
| 37511442 | Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37511442 | PubMed |
| 37444534 | State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37444534 | PubMed |
| 36810257 | The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. | JCI Insight | 2023 | https://conductscience.org/library/papers/36810257 | PubMed |
| 36644397 | ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe. | NAR Cancer | 2023 | https://conductscience.org/library/papers/36644397 | PubMed |
| 36413415 | ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. | JCI Insight | 2022 | https://conductscience.org/library/papers/36413415 | PubMed |
| 36130512 | Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression. | Cell Rep | 2022 | https://conductscience.org/library/papers/36130512 | PubMed |
| 35205643 | Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35205643 | PubMed |
| 34964992 | Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. | Mol Carcinog | 2022 | https://conductscience.org/library/papers/34964992 | PubMed |
| 34224364 | VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases. | Mol Cancer Ther | 2021 | https://conductscience.org/library/papers/34224364 | PubMed |
| 34027408 | Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. | NAR Cancer | 2021 | https://conductscience.org/library/papers/34027408 | PubMed |
| 34021944 | Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications. | Oncologist | 2021 | https://conductscience.org/library/papers/34021944 | PubMed |
| 33905873 | Critical DNA damaging pathways in tumorigenesis. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/33905873 | PubMed |
Genes28
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25965342
GET https://conductscience.org/api/papers/v1/25965342/references?page=2